Can Daraxonrasib Reshape Pancreatic Cancer Care? Experts Weigh Promise and Limits
Pancreatic cancer remains one of the most formidable malignancies. Because early-stage disease rarely produces distinct symptoms, many cases have...
Search results for "South Korean biotech"
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour
Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s obesity drug candidate "EPPE" has...
Celltrion Files for South Korean Approval of Keytruda Biosimilar CT-P51
Celltrion announced on August 24 that it has submitted a marketing authorization application to South Korea’s Ministry...
From Liposuction Waste to Skin Models: Discarded Human Fat Repurposed for Medical Research
Human fat once discarded as medical waste after liposuction is set to take on new life as a crucial material for...
Moderna’s Landmark mRNA Cancer Vaccine Phase 3 Success Spotlights Korean Biotech Ties
Positive late-stage clinical results for a personalized messenger RNA cancer vaccine developed by Moderna and Merck are...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care
Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway
"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
South Korea Overhauls Pharma and Biotech Disclosure Rules Following Samchundang Controversy
South Korean financial authorities are overhauling disclosure regulations across the pharmaceutical and biotechnology...
Eli Lilly Licensing Deal Surge: Hanmi Pharmaceutical’s Q2 Operating Profit Jumps 117%
Hanmi Pharmaceutical posted a sharp profit surge in the second quarter of this year, buoyed by a major...